The Experts below are selected from a list of 27492 Experts worldwide ranked by ideXlab platform
Antoine Dupuis - One of the best experts on this subject based on the ideXlab platform.
-
Preparation and physicochemical stability of 50 mg/mL Hydroxychloroquine oral suspension in SyrSpend(Ⓡ) SF PH4 (dry)
International Journal of Antimicrobial Agents, 2020Co-Authors: Guillaume Binson, Nicolas Venisse, Alexis Sauvaget, Astrid Bacle, Pauline Lazaro, Antoine DupuisAbstract:In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, Hydroxychloroquine has been proposed as a potential agent to treat patients with COVID-19 (coronavirus disease 2019) caused by SARS-CoV-2 infection. Older adults are more susceptible to COVID-19 and some patients may require admission to the intensive care unit, where oral drug administration of solid forms may be compromised in many COVID-19 patients. However, a liquid formulation of Hydroxychloroquine is not commercially available. This study describes how to prepare a 50 mg/mL Hydroxychloroquine oral suspension using Hydroxychloroquine sulfate powder and SyrSpend(Ⓡ) SF PH4 (dry) suspending vehicle. Moreover, a fully validated stability-indicating method has been developed to demonstrate the physicochemical stability of the compounded Hydroxychloroquine oral suspension over 60 days under refrigeration (5 ± 3 °C). Finally, use of the proposed oral suspension provides a reliable solution to perform safe and accurate administration of Hydroxychloroquine to patients with SARS-CoV-2 infection.
Guillaume Binson - One of the best experts on this subject based on the ideXlab platform.
-
Preparation and physicochemical stability of 50 mg/mL Hydroxychloroquine oral suspension in SyrSpend(Ⓡ) SF PH4 (dry)
International Journal of Antimicrobial Agents, 2020Co-Authors: Guillaume Binson, Nicolas Venisse, Alexis Sauvaget, Astrid Bacle, Pauline Lazaro, Antoine DupuisAbstract:In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, Hydroxychloroquine has been proposed as a potential agent to treat patients with COVID-19 (coronavirus disease 2019) caused by SARS-CoV-2 infection. Older adults are more susceptible to COVID-19 and some patients may require admission to the intensive care unit, where oral drug administration of solid forms may be compromised in many COVID-19 patients. However, a liquid formulation of Hydroxychloroquine is not commercially available. This study describes how to prepare a 50 mg/mL Hydroxychloroquine oral suspension using Hydroxychloroquine sulfate powder and SyrSpend(Ⓡ) SF PH4 (dry) suspending vehicle. Moreover, a fully validated stability-indicating method has been developed to demonstrate the physicochemical stability of the compounded Hydroxychloroquine oral suspension over 60 days under refrigeration (5 ± 3 °C). Finally, use of the proposed oral suspension provides a reliable solution to perform safe and accurate administration of Hydroxychloroquine to patients with SARS-CoV-2 infection.
Jennifer L Rogers - One of the best experts on this subject based on the ideXlab platform.
-
Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.
Current allergy and asthma reports, 2021Co-Authors: Akrithi Udupa, David L. Leverenz, Stephen J. Balevic, Rebecca E Sadun, Teresa K. Tarrant, Jennifer L RogersAbstract:Purpose of review Told from the viewpoint of rheumatologists, this review tells the story of Hydroxychloroquine and its swift ascent to become a household name as a therapeutic strategy against the novel SARS-CoV-2 virus. This review describes the history, mechanisms, pharmacokinetics, therapeutic applications, and safety profile of Hydroxychloroquine as an immunomodulatory and antiviral agent. It also summarizes the major studies that launched and assessed the use of Hydroxychloroquine against COVID-19 infection. Recent findings More recent literature calls into question the long-held dogma that endolysosomal alkalinization is the primary mode of action of Hydroxychloroquine. Ongoing uncertainty about the multiple potential mechanisms contributing to the therapeutic effect of Hydroxychloroquine in rheumatic and viral disease led to a natural avenue for exploration in the treatment of COVID-19. Taken as a whole, the literature does not support utilizing Hydroxychloroquine to treat or prevent infection from the SARS-CoV-2 virus. This is, at least in part, due to the wide variability in Hydroxychloroquine pharmacokinetics between patients and difficulty achieving adequate target tissue concentrations of Hydroxychloroquine without encountering unacceptable toxicities. Hydroxychloroquine continues to be a routinely prescribed, well-tolerated, effective, and low-cost treatment for rheumatic disease. Its therapeutic versatility has led to frequent repurposing for other conditions, most recently as an investigative treatment against the SARS-CoV-2 virus. Despite overall negative findings, the intense study of Hydroxychloroquine against COVID-19 infection has enhanced our overall understanding of how Hydroxychloroquine operates in autoimmune disease and beyond.
-
Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.
Current allergy and asthma reports, 2021Co-Authors: Akrithi Udupa, David L. Leverenz, Stephen J. Balevic, Rebecca E Sadun, Teresa K. Tarrant, Jennifer L RogersAbstract:Told from the viewpoint of rheumatologists, this review tells the story of Hydroxychloroquine and its swift ascent to become a household name as a therapeutic strategy against the novel SARS-CoV-2 virus. This review describes the history, mechanisms, pharmacokinetics, therapeutic applications, and safety profile of Hydroxychloroquine as an immunomodulatory and antiviral agent. It also summarizes the major studies that launched and assessed the use of Hydroxychloroquine against COVID-19 infection. More recent literature calls into question the long-held dogma that endolysosomal alkalinization is the primary mode of action of Hydroxychloroquine. Ongoing uncertainty about the multiple potential mechanisms contributing to the therapeutic effect of Hydroxychloroquine in rheumatic and viral disease led to a natural avenue for exploration in the treatment of COVID-19. Taken as a whole, the literature does not support utilizing Hydroxychloroquine to treat or prevent infection from the SARS-CoV-2 virus. This is, at least in part, due to the wide variability in Hydroxychloroquine pharmacokinetics between patients and difficulty achieving adequate target tissue concentrations of Hydroxychloroquine without encountering unacceptable toxicities. Hydroxychloroquine continues to be a routinely prescribed, well-tolerated, effective, and low-cost treatment for rheumatic disease. Its therapeutic versatility has led to frequent repurposing for other conditions, most recently as an investigative treatment against the SARS-CoV-2 virus. Despite overall negative findings, the intense study of Hydroxychloroquine against COVID-19 infection has enhanced our overall understanding of how Hydroxychloroquine operates in autoimmune disease and beyond.
-
Hydroxychloroquine and COVID-19: a Rheumatologist’s Take on the Lessons Learned
Current Allergy and Asthma Reports, 2021Co-Authors: Akrithi Udupa, David L. Leverenz, Stephen J. Balevic, Rebecca E Sadun, Teresa K. Tarrant, Jennifer L RogersAbstract:Purpose of Review Told from the viewpoint of rheumatologists, this review tells the story of Hydroxychloroquine and its swift ascent to become a household name as a therapeutic strategy against the novel SARS-CoV-2 virus. This review describes the history, mechanisms, pharmacokinetics, therapeutic applications, and safety profile of Hydroxychloroquine as an immunomodulatory and antiviral agent. It also summarizes the major studies that launched and assessed the use of Hydroxychloroquine against COVID-19 infection. Recent Findings More recent literature calls into question the long-held dogma that endolysosomal alkalinization is the primary mode of action of Hydroxychloroquine. Ongoing uncertainty about the multiple potential mechanisms contributing to the therapeutic effect of Hydroxychloroquine in rheumatic and viral disease led to a natural avenue for exploration in the treatment of COVID-19. Taken as a whole, the literature does not support utilizing Hydroxychloroquine to treat or prevent infection from the SARS-CoV-2 virus. This is, at least in part, due to the wide variability in Hydroxychloroquine pharmacokinetics between patients and difficulty achieving adequate target tissue concentrations of Hydroxychloroquine without encountering unacceptable toxicities. Summary Hydroxychloroquine continues to be a routinely prescribed, well-tolerated, effective, and low-cost treatment for rheumatic disease. Its therapeutic versatility has led to frequent repurposing for other conditions, most recently as an investigative treatment against the SARS-CoV-2 virus. Despite overall negative findings, the intense study of Hydroxychloroquine against COVID-19 infection has enhanced our overall understanding of how Hydroxychloroquine operates in autoimmune disease and beyond.
Alexis Sauvaget - One of the best experts on this subject based on the ideXlab platform.
-
Preparation and physicochemical stability of 50 mg/mL Hydroxychloroquine oral suspension in SyrSpend(Ⓡ) SF PH4 (dry)
International Journal of Antimicrobial Agents, 2020Co-Authors: Guillaume Binson, Nicolas Venisse, Alexis Sauvaget, Astrid Bacle, Pauline Lazaro, Antoine DupuisAbstract:In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, Hydroxychloroquine has been proposed as a potential agent to treat patients with COVID-19 (coronavirus disease 2019) caused by SARS-CoV-2 infection. Older adults are more susceptible to COVID-19 and some patients may require admission to the intensive care unit, where oral drug administration of solid forms may be compromised in many COVID-19 patients. However, a liquid formulation of Hydroxychloroquine is not commercially available. This study describes how to prepare a 50 mg/mL Hydroxychloroquine oral suspension using Hydroxychloroquine sulfate powder and SyrSpend(Ⓡ) SF PH4 (dry) suspending vehicle. Moreover, a fully validated stability-indicating method has been developed to demonstrate the physicochemical stability of the compounded Hydroxychloroquine oral suspension over 60 days under refrigeration (5 ± 3 °C). Finally, use of the proposed oral suspension provides a reliable solution to perform safe and accurate administration of Hydroxychloroquine to patients with SARS-CoV-2 infection.
Pauline Lazaro - One of the best experts on this subject based on the ideXlab platform.
-
Preparation and physicochemical stability of 50 mg/mL Hydroxychloroquine oral suspension in SyrSpend(Ⓡ) SF PH4 (dry)
International Journal of Antimicrobial Agents, 2020Co-Authors: Guillaume Binson, Nicolas Venisse, Alexis Sauvaget, Astrid Bacle, Pauline Lazaro, Antoine DupuisAbstract:In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, Hydroxychloroquine has been proposed as a potential agent to treat patients with COVID-19 (coronavirus disease 2019) caused by SARS-CoV-2 infection. Older adults are more susceptible to COVID-19 and some patients may require admission to the intensive care unit, where oral drug administration of solid forms may be compromised in many COVID-19 patients. However, a liquid formulation of Hydroxychloroquine is not commercially available. This study describes how to prepare a 50 mg/mL Hydroxychloroquine oral suspension using Hydroxychloroquine sulfate powder and SyrSpend(Ⓡ) SF PH4 (dry) suspending vehicle. Moreover, a fully validated stability-indicating method has been developed to demonstrate the physicochemical stability of the compounded Hydroxychloroquine oral suspension over 60 days under refrigeration (5 ± 3 °C). Finally, use of the proposed oral suspension provides a reliable solution to perform safe and accurate administration of Hydroxychloroquine to patients with SARS-CoV-2 infection.
